Etienne Guillot

Sanofi R&D
Chilly, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure.

Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure.

Journal: Journal of the American College of Cardiology

Published: June 23, 2023

High Glucose Activates YAP Signaling to Promote Vascular Inflammation.

High Glucose Activates YAP Signaling to Promote Vascular Inflammation.

Journal: Frontiers in physiology

Published: February 09, 2021

Apelin improves cardiac function mainly through peripheral vasodilation in a mouse model of dilated cardiomyopathy.

Apelin improves cardiac function mainly through peripheral vasodilation in a mouse model of dilated cardiomyopathy.

Journal: Peptides

Published: December 10, 2020

Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.

Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.

Journal: The Journal of pharmacology and experimental therapeutics

Published: January 30, 2020

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab.

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab.

Journal: JACC. Basic to translational science

Published: December 26, 2019

Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis.

Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis.

Journal: mAbs

Published: February 05, 2019

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

Journal: Clinical science (London, England : 1979)

Published: January 16, 2018

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

Journal: Clinical science (London, England : 1979)

Published: October 18, 2016

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.

Journal: JACC. Basic to translational science

Published: October 01, 2016

Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitors.

Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: October 02, 2015

Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.

Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.

Journal: Bioorganic & medicinal chemistry letters

Published: April 04, 2013

Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).

Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).

Journal: Bioorganic & medicinal chemistry letters

Published: January 23, 2013

Showing 1-12 of 17

Last Updated: 09/26/2026